• -Untersuchungend Häufig ALT erhöht, AST erhöht
• +Untersuchungene Häufig ALT erhöht, AST erhöht
• +Revisions-Historie
• +Gesuchs ID Meilenstein Grund der Einreichung Initialen des Gutachtersls
• +102658307 Initial Submission MAA according to Art. 13 TPA, text according to approved EU-SmPC, amendments according to Swissmedic’s template and guidance PharmaContext
• +102658307 Response to Preliminary Decree Response to Preliminary Decree, Update of MAH, Deletion of pack with 98 capsules Response to Preliminary Decree
• +102690352 Label update – Desogestrel – Initial submission Label update for interaction with desogestrel and minor corrections Desogestrel
• +102741102 Type 1AIN variation – Response to Safety Signal Notification. Signal No. 102739454, approved 13 Nov 2024 Revised wording to add postmarketing adverse event for nausea BCRX Type 1AIN
• +102737333 Type II variation – Study 119 Initial Submission Label update for interaction with ciclosporine. Clarification to Warnings and Precautions requested by EMA. BCRX
• +
• +